Treatment of type 2 diabetes with GLP-1 receptor agonists originally required subcutaneous injection of a peptide analog of the GLP-1 hormone. Oral semaglutide allows an oral form of administration that overcomes patients' fear of injections and improves treatment adherence[1]. It is administered in a single daily dose from an initial 3 mg to a target of 14 mg, taken with a glass of water and a 30-minute fast from food, liquids, and other medications[1]. Compared to empagliflozin, it brought about a significantly better reduction of glycated hemoglobin after 26 and 52 weeks and after 52 weeks a more significant loss of body weight[1]. Oral semaglutide has a long half-life, which facilitates daily dosing, especially in patients with limited mobility[1]. GLP-1 agonists, including semaglutide, compete for higher efficacy and better tolerability in the treatment of diabetes[1]. Side effects include gastrointestinal intolerance such as nausea or diarrhea, which is often transient[2].